TY - JOUR
T1 - Sleep abnormalities in the synaptopathies—SYNGAP1-related intellectual disability and Phelan–McDermid syndrome
AU - Smith-Hicks, Constance
AU - Wright, Damien
AU - Kenny, Aisling
AU - Stowe, Robert C.
AU - McCormack, Maria
AU - Stanfield, Andrew C.
AU - Holder, J. Lloyd
N1 - Funding Information:
Funding: J.L.H. and C.S.H. received funding for this study from Bridge the Gap: SYNGAP1 Education and Research Fund. A.C.S. received funding for this study from the Simons Initiative for the Developing Brain and the Patrick Drake Wild Fund. J.L.H. also gratefully acknowledges the generous support of the Joan and Stanford Alexander Family Foundation as well as The Robbins Foundation and Charif Souki.
Funding Information:
Acknowledgments: We are deeply indebted to all of the participants and their caregivers that participated in this study. We also are grateful to the patient advocacy foundations: Phelan–McDermid Syndrome Foundation, SynGap Research Fund, Inc. and Bridge the Gap: SYNGAP1 Education and Research Foundation, which aided in patient recruitment.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/9/17
Y1 - 2021/9/17
N2 - Neurodevelopmental disorders are frequently associated with sleep disturbances. One class of neurodevelopmental disorders, the genetic synaptopathies, is caused by mutations in genes encoding proteins found at the synapse. Mutations in these genes cause derangement of synapse development and function. We utilized a validated sleep instrument, Children’s Sleep Habits Questionnaire (CSHQ) to examine the nature of sleep abnormalities occurring in individuals with two synaptopathies—Phelan–McDermid syndrome (PMD) (N = 47, male = 23, female = 24, age 1–46 years) and SYNGAP1-related intellectual disability (SYNGAP1-ID) (N = 64, male = 31, female = 33, age 1–64 years), when compared with unaffected siblings (N = 61, male = 25, female = 36, age 1–17 years). We found that both PMD and SYNGAP1-ID have significant sleep abnormalities with SYNGAP1-ID having greater severity of sleep disturbance than PMD. In addition, sleep disturbances were more severe for PMD in individuals 11 years and older compared with those less than 11 years old. Individuals with either disorder were more likely to use sleep aids than unaffected siblings. In conclusion, sleep disturbances are a significant phenotype in the synaptopathies PMD and SYNGAP1-ID. Improved sleep is a viable endpoint for future clinical trials for these neurodevelopmental disorders.
AB - Neurodevelopmental disorders are frequently associated with sleep disturbances. One class of neurodevelopmental disorders, the genetic synaptopathies, is caused by mutations in genes encoding proteins found at the synapse. Mutations in these genes cause derangement of synapse development and function. We utilized a validated sleep instrument, Children’s Sleep Habits Questionnaire (CSHQ) to examine the nature of sleep abnormalities occurring in individuals with two synaptopathies—Phelan–McDermid syndrome (PMD) (N = 47, male = 23, female = 24, age 1–46 years) and SYNGAP1-related intellectual disability (SYNGAP1-ID) (N = 64, male = 31, female = 33, age 1–64 years), when compared with unaffected siblings (N = 61, male = 25, female = 36, age 1–17 years). We found that both PMD and SYNGAP1-ID have significant sleep abnormalities with SYNGAP1-ID having greater severity of sleep disturbance than PMD. In addition, sleep disturbances were more severe for PMD in individuals 11 years and older compared with those less than 11 years old. Individuals with either disorder were more likely to use sleep aids than unaffected siblings. In conclusion, sleep disturbances are a significant phenotype in the synaptopathies PMD and SYNGAP1-ID. Improved sleep is a viable endpoint for future clinical trials for these neurodevelopmental disorders.
KW - Children’s Sleep Habits Questionnaire
KW - Phelan–Mcdermid syndrome
KW - Polysomnography
KW - SYNGAP1
UR - https://www.scopus.com/pages/publications/85115649533
U2 - 10.3390/brainsci11091229
DO - 10.3390/brainsci11091229
M3 - Article
AN - SCOPUS:85115649533
SN - 2076-3425
VL - 11
JO - Brain Sciences
JF - Brain Sciences
IS - 9
M1 - 1229
ER -